Overview of the drug development for onychomycosis
It has been observed that fungal infection in the nails is the common cause for onychomycosis and is characterized by degeneration of the nails due to the invasion of organisms. Onychomycosis is a broad term and does not only include disease caused due to dermatophytes but also includes infections caused by yeasts and saprophytic molds. Distal and lateral subungual onychomycosis is characterized by invasion of the nail bed and underside of the nail plate, beginning at the hyponychium. Proximal subungual onychomycosis occurs when organisms invade the nail unit via the proximal nail fold through the cuticle area, penetrate the newly formed plate, and migrate distally. White superficial onychomycosis generally occurs when certain fungi invade the superficial layers of the nail plate directly while when the organism invades the entire nail plate it is commonly referred as candida onychomycosis. Topical treatment via application of nail lacquers is emerging as the most efficient approach for the treatment of onychomycosis.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for distal and lateral subungual onychomycosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
Pipeline analysis report on drug development for onychomycosis: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of onychomycosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Crescita Therapeutics
- Global Health Solutions
- Blueberry Therapeutics
Therapeutic assessment of the drug development pipeline for Onychomycosis by route of administration
- Topical
- Oral
- Subungual
- Transdermal
- Unspecified
The topical route of administration (ROA) involves the application of the drug directly on the skin, which will have a more direct effect on the target cells for the treatment of onychomycosis. Oral ROA involves delivery of the drug through the mouth cavity while the subungual administration is done by diffusing the drug into the blood through tissues under the nail. Transdermal administration involves administering the drug across the skin for systematic distribution.
Therapeutic assessment of the drug development pipeline for Onychomycosis by therapy
- Monotherapy
According to this pipeline analysis report, all the molecules that are currently in the drug pipeline for treatment of onychomycosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug therapy molecules in the various development stages for onychomycosis?
- What are the companies that are currently involved in the development of drug molecules for onychomycosis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.